Ophthotech starts Phase IIb of Zimura for Stargardt disease

Ophthotech Corp. (NASDAQ:OPHT) began a double-blind, sham-controlled Phase IIb trial to evaluate intravitreal Zimura avacincaptad pegol for 18 months in about 120 patients with autosomal recessive Stargardt disease 1. The company expects top-line data in 2020.

The primary endpoint is the mean rate of change in the area of ellipsoid zone defect measured by en face Spectral Domain-Optical Coherence Tomography (SD-OCT)...